- Home
- III vs VTYX Comparison
III vs VTYX Comparison
Compare III & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- VTYX
- Stock Information
- Founded
- III 2006
- VTYX 2018
- Country
- III United States
- VTYX United States
- Employees
- III N/A
- VTYX N/A
- Industry
- III Professional Services
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- III Consumer Discretionary
- VTYX Health Care
- Exchange
- III Nasdaq
- VTYX Nasdaq
- Market Cap
- III 176.6M
- VTYX 154.9M
- IPO Year
- III 2007
- VTYX 2021
- Fundamental
- Price
- III $3.72
- VTYX $1.07
- Analyst Decision
- III Buy
- VTYX Buy
- Analyst Count
- III 1
- VTYX 4
- Target Price
- III $3.75
- VTYX $11.33
- AVG Volume (30 Days)
- III 146.1K
- VTYX 1.4M
- Earning Date
- III 05-08-2025
- VTYX 05-08-2025
- Dividend Yield
- III 4.86%
- VTYX N/A
- EPS Growth
- III N/A
- VTYX N/A
- EPS
- III 0.06
- VTYX N/A
- Revenue
- III $247,585,000.00
- VTYX N/A
- Revenue This Year
- III N/A
- VTYX N/A
- Revenue Next Year
- III $5.20
- VTYX N/A
- P/E Ratio
- III $63.92
- VTYX N/A
- Revenue Growth
- III N/A
- VTYX N/A
- 52 Week Low
- III $2.92
- VTYX $0.78
- 52 Week High
- III $4.05
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- III 56.49
- VTYX 42.90
- Support Level
- III $3.42
- VTYX $1.02
- Resistance Level
- III $3.87
- VTYX $1.18
- Average True Range (ATR)
- III 0.18
- VTYX 0.11
- MACD
- III -0.03
- VTYX 0.03
- Stochastic Oscillator
- III 47.62
- VTYX 65.98
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.